Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Nivolumab for Metastatic Solid Tumors
NCT03525925Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibrutinib in metastatic solid tumor, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Jul 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT03525925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525925.